IVF Hartmann Holding AG (VBSN.SW) fair value

ACCE thesis

IVF Hartmann makes single-use diagnostic and fertility-related consumables, including pregnancy and ovulation test kits and reproductive medicine supplies, sold largely to pharmacies, clinics and laboratories. Its advantage is a niche, regulated product set where recurring disposable demand and a 54.3% gross margin reflect pricing power that a sub-300M CHF company rarely has. Revenue grew 11.3% and the operating margin sits at 14.1%, so growth is coming with real profitability rather than at its expense. The stock trades at 14.5 times trailing earnings, a modest multiple for a business compounding sales at double digits with a 13.5% return on equity. The obvious question for a portfolio manager is whether that growth is durable outside a single product cycle, and whether the margin can hold as the company scales, which justifies a look at the filings and segment detail before any further decision.